MeSH

A work that reports on a clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

Year introduced: 2008(1991)

Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

Year introduced: 2008(1990)

A work that reports on a clinical trial with animal subjects that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

Year introduced: 2020

A work that reports on a clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterized as a RANDOMIZED CONTROLLED TRIAL.

Year introduced: 2008(1995)

a pink powder that contains multiple vitamins and minerals along with grape seed and pine bark extract with Gingko biloba, lycopene, bilberry, lutein and other nutritional components; a food supplement that increases energy levels in healthy adults; in phase IIb randomized controlled trial (7/2008)

Date introduced: December 24, 2008

contains plasmid-DNA-encoding fragments derived from the E6 and E7 proteins of human papillomavirus (HPV) 16 and 18, and is formulated within small biodegradable microparticles; for treatment of high-grade cervical intraepithelial neoplasia, in a randomized controlled trial (2/2004)

Date introduced: March 4, 2004

Trial that aims to show a new treatment is no better and no worse than the standard treatment.

Year introduced: 2018